Who are ABP 710's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SB5 (Adalimumab Biosimilar), CT-P17 SC AI (adalimumab), AVT03, MYL-1401A (Adalimumab), GP2017 Adalimumab, Adalimumab - GP2017.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abp-710.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ABP 710 — Competitive Intelligence Brief

ABP 710 (ABP 710) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody biosimilar). Area: Immunology / Rheumatology.

phase 3 TNF-α inhibitor (monoclonal antibody biosimilar) TNF-α (tumor necrosis factor-alpha) Immunology / Rheumatology Biologic Live · refreshed every 30 min

Target snapshot

ABP 710 (ABP 710) — Amgen. ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABP 710 TARGET	ABP 710	Amgen	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
SB5 (Adalimumab Biosimilar)	SB5 (Adalimumab Biosimilar)	Samsung Bioepis Co., Ltd.	marketed	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
CT-P17 SC AI (adalimumab)	CT-P17 SC AI (adalimumab)	Celltrion	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
AVT03	AVT03	Alvotech Swiss AG	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
MYL-1401A (Adalimumab)	MYL-1401A (Adalimumab)	Mylan Inc.	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (Tumor Necrosis Factor-alpha)
GP2017 Adalimumab	GP2017 Adalimumab	Sandoz	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)
Adalimumab - GP2017	Adalimumab - GP2017	Sandoz	phase 3	TNF-α inhibitor (monoclonal antibody biosimilar)	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody biosimilar) class)

Sandoz · 2 drugs in this class
Alvotech Swiss AG · 1 drug in this class
Amgen · 1 drug in this class
Celltrion · 1 drug in this class
Mylan Inc. · 1 drug in this class
Samsung Bioepis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABP 710 — Competitive Intelligence Brief. https://druglandscape.com/ci/abp-710. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab